Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 1, 2008, Pages 23-30

  Neves, Gilda ^a   Kliemann, Michele ^a   Betti, Andresa H ^a   Conrado, Daniela J ^a   Tasso, Leandro ^a   Fraga, Carlos A M ^b   Barreiro, Eliezer J ^b   Teresa Dalla Costa, ^a   Rates, Stela M K ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antipsychotics; Hypothermia; LASSBio 579; LASSBio 581; N phenylpiperazine derivatives; Schizophrenia

Indexed keywords

1 [1 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 4 YLMETHYL] 4 PHENYLHEXAHYDROPYRAZINE; 1 [1 (4 CHLOROPHENYL) 1H 4 PYRAZOLYLMETHYL] 4 PHENYLHEXAHYDROPYRAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; HALOPERIDOL; LASSBIO 579; LASSBIO 581; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; INDUCED HYPOTHERMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC TRANSMISSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; HALOPERIDOL; HYPOTHERMIA; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PIPERAZINES; PYRIDINES; SEROTONIN; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

MUS;

EID: 38049178119     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.10.018     Document Type: Article

References (48)

1. Alvarado M., Coelho A., Masaquer C.F., Ravina E., Brea J., Padin J.F., et al. Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics. Bioorg Med Chem Lett 15 (2005) 3063-3066
2. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14 (2004) 281-299
3. Araneda R., and Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40 (1991) 399-412
4. Assié M., Ravailhe V., Faucillon V., and Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315 (2005) 265-272
5. Backus L.I., Sharp T., and Grahame-Smith D.G. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol 100 (1990) 793-799
6. Brea J., Castro M., Loza M.I., Masaquer C.F., Ravina E., Dezi C., et al. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology 51 (2006) 251-262
7. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 (2005) 996-1006
8. Conrado DJ. Avaliação pré-clínica em ratos do perfil farmacocinético da substância LASSBio-579 [Master's Thesis]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2006.
9. 2 receptors?. Pharmacol Biochem Behav 36 (1990) 901-906
10. 2-receptor interactions. Pharmacol Biochem Behav 37 (1990) 95-99
11. Darmani N.A., Shaddy J., and Gerdes C.F. Differential ontogenesis of three DOI-induced behaviors in mice. Physiol Behav 60 (1996) 1495-1500
12. Dursun S.M., and Handley S.L. Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5HT2A receptors are active under physiological conditions. Psychopharmacology 128 (1996) 198-205
13. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiat 7 (2005) 268-274
14. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281 (1995) 81-88
15. Gardner D.M., Baldessarini R.J., and Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 172 (2005) 1703-1711
16. Garzya V., Forbes I.T., Gribble A.D., Hadley M.S., Lightfoot A.P., Payne A.H., et al. Studies towards the identification of new generation of atypical antipsychotic agents. Bioorg Med Chem Lett 17 (2007) 400-405
17. Goodwin G.M., De Souza R.J., and Green A.R. The pharmacology of the hypothermic response in mice to 8-hydrozy-2-(di-n-propylamino)tetralin (8-OH-DPAT): a model of presynaptic 5-HT1 function. Neuropharmacology 24 (1985) 1187-1194
18. Haleem D.J., Shireen E., and Haleem M.A. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1323-1329
19. Hirose T., Uwahodo Y., Yamada S., Miwa T., Kikuchi T., Kitagawa H., et al. Mechanism of action of aripiprazole predicts efficacy and a favourable side-effect profile. J Psychopharmacol 18 (2004) 375-383
20. Ichikawa J., and Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 249 Suppl. 4 (1998) S90-S98
21. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76 (2001) 1521-1531
22. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153 (1996) 466-476
23. Kitamura Y., Araki H., Shibata K., Gomita Y., and Tanizaki Y. Modulation of 8-OH-DPAT-induced hypothermia by imipramine in rats. J Pharmacol Sci 93 (2003) 259-264
24. Krebs-Thomson K., and Geyer M.A. Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology (Berl) 140 (1998) 69-74
25. Marek G.J. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotics drug development. Int Rev Neurobiol 78 (2007) 165-192
26. Marek G., and Merchant K. Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRX 2 (2005) 579-589
27. Maswood N., and Uphouse L. Modulation of the behavioral effects of 8-OH-DPAT by estrogen and DOI. Pharmacol Biochem Behav 58 (1997) 859-866
28. Matsui-Sakata A., Ohtani H., and Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 20 (2005) 187-199
29. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3 (1995) 64-75
30. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1159-1172
31. 2 receptor ligands. Bioorg Med Chem 11 (2003) 4807-4813
32. 1A receptors. J Pharmacol Exp Ther 295 (2000) 853-861
33. Millan M.J., Rivet J.M., Canton H., Le Marouille-Girardon S., and Gobert A. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. J Pharmacol Exp Ther 264 (1993) 1364-1376
34. Neves G., Fenner R., Heckler A.P., Viana A.F., Tasso L., Menegatti R., et al. Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives. Braz J Med Biol Res 36 (2003) 625-629
35. Ninan I., and Kulkarni S.K. Antagonism by pimozide of olanzapine-induced hypothermia. Fundam Clin Pharmacol 13 (1999) 541-546
36. 1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 292 (2000) 731-736
37. Owens D.G.C. Adverse effects of antipsychotic agents: do newer agents offer advantages?. Drugs 51 (1996) 895-930
38. Park W.K., Jeong D., Cho H., Lee S.J., Cha M.Y., Pae A.N., et al. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacol Biochem Behav 82 (2005) 361-372
39. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 144 (1999) 20-29
40. 2A receptors in rat thermoregulatory mechanisms. Pharmacol Toxicol 82 (1998) 122-127
41. Schotte A., Janssen P.F.M., Megens A.A.H.P., and Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 631 (1993) 191-202
42. Schwartz P.J., Wehr T.A., Rosenthal N.E., Bartko J.J., Oren D.A., Leutke C., et al. Serotonin and thermoregulation: physiologic and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects. Neuropsychopharmacology 13 (1995) 105-115
43. Stahl S.M. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. (2000), Cambridge University Press, New York
44. Tasso L., Neves G., Menegatti R., Fraga C.A.M., Barreiro E., Eifler-Lima V., et al. Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. Eur J Pharm Sci 26 (2005) 194-202
45. Wadenberg M.L. Serotonergic mechanism in neuroleptics-induced catalepsy in the rat. Neurosci Biobehav Rev 20 (1996) 325-339
46. Wermuth C.G. The practice of medicinal chemistry. 3rd ed. (2006), Elsevier Academic Press, Amsterdam
47. Wong A.H., and Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 27 (2003) 269-306
48. 2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-amunopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice. Biol Pharm Bull 18 (1995) 1580-1583